Noltec
(Ilaprazole)Phase 3Small molecule
Ilaprazole is used to treat conditions caused by excess stomach acid, such as acid reflux and peptic ulcers. It works by reducing the amount of acid your stomach produces.[1] Noltec is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
Noltec is one of 147 small molecule programs targeting Duodenal Ulcer. It is currently in Phase 3.
5
Indications
24
Total Trials
1
Active Trials
146
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
137 competitors in Hemorrhage
#DrugCompanyPhaseTrials
1Noltec
LLivzon Pharmaceutical Group Inc.
Phase 3
Cytotec
PfizerPhase 3
Cyklokapron
AAmring
Phase 3
Activase
RochePhase 3
Glypressin
MMallinckrodt
Phase 3
Virazole
CConrado Roberto Hoffmann Filho
Phase 3
Tylenol
KKenvue Brands
Phase 3
Indocin
LLife Extension Foundation Inc.
Phase 3
Zocor
OOrganon and Co
Phase 3
Betadine
BBecton, Dickinson and Company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Duodenal Ulcer4 trials
Drug Interactions3 trials
Peptic ulcer3 trials
Gastroesophageal Reflux Disease2 trials
11 more indications
Pilot Study1 trial
Treatment1 trial
Efficacy and Safety1 trial
Esophagitis1 trial
Helicobacter Pylori Infection1 trial
Helicobacter Pylori1 trial
Genetic Polymorphism1 trial
GastroIntestinal Bleeding1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ilaprazole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Potassium-Transporting Atpase Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLivzon Pharmaceutical Group Inc.